Computational Biologist – Obesity Research at Eli Lilly and Company

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Pharmaceuticals, BiotechnologyIndustries

Requirements

Passionate about addressing global health challenges in metabolic disease research and obesity pathophysiology
Stay current with the latest advances in metabolic disease research and obesity pathophysiology
Deep expertise in obesity biology and computational methods
Ability to design and implement multi-omic studies focused on obesity pathophysiology, energy regulation, adipose tissue biology, metabolic pathway dysregulation, and CNS pathways
Experience analyzing single-cell genomics data from preclinical models and human studies
Proficiency in applying established computational methods and pioneering AI/ML approaches to multi-omics and multi-modal datasets
Team-oriented and collaborative with cross-functional researchers, experimental project leads, and scientific domain experts

Responsibilities

Design and complete studies using omics-related data sources, including RNA-seq, spatial transcriptomics, single-cell omics, proteomics, functional genomics, metabolomics, and more
Integrate standard analytical approaches as well as emerging AI/ML models to answer scientific questions of high-dimensional data
Partner with discovery statistics team to create novel analytical frameworks for high-throughput studies and develop specialized methodologies to enhance insights from small-sample datasets
Stay up-to-date on current technical and scientific advances through deep understanding of the literature and attendance of relevant technical and disease-related conferences
Clearly communicate complex results to cross-functional partners in a prompt and transparent manner
Perform ad-hoc bioinformatics analyses and data visualizations as needed
Work collaboratively with other Data Sciences and Computational Biology (DSCB) scientists to develop innovative, best in class computational workflows and data repositories for advanced analyses
Engage in code and documentation review

Skills

Computational Biology

Multi-omics

Statistical Analysis

Obesity Biology

Adipose Tissue

Metabolic Dysregulation

Biologics

Small Molecule

Nucleic Acid Therapeutics

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free